ID   OCI-Ly1
AC   CVCL_1879
SY   OCI-LY1; OCI-ly1; OCI-LY-1; OCI-Ly-1; Oci-Ly-1; OCI-Ly 1; OCI-Ly01; OCI Ly1; Ly1; LY1
DR   EFO; EFO_0005907
DR   Cosmic; 1134602
DR   Cosmic; 1295512
DR   Cosmic; 1329091
DR   Cosmic; 1517641
DR   Cosmic; 1541900
DR   Cosmic; 1629932
DR   Cosmic; 1636682
DR   Cosmic; 1945183
DR   Cosmic; 2276318
DR   DSMZ; ACC-722
DR   ENCODE; ENCBS397COL
DR   ENCODE; ENCBS729LWO
DR   ENCODE; ENCBS899DSB
DR   ENCODE; ENCBS945KYE
DR   GEO; GSM1957
DR   GEO; GSM380130
DR   GEO; GSM552450
DR   GEO; GSM1035341
DR   GEO; GSM1059803
DR   GEO; GSM1374783
DR   Lonza; 1352
DR   Progenetix; CVCL_1879
DR   Wikidata; Q54931759
RX   PubMed=3567358;
RX   PubMed=8574164;
RX   PubMed=10676951;
RX   PubMed=11807979;
RX   PubMed=12169673;
RX   PubMed=19278952;
RX   PubMed=19358282;
RX   PubMed=23292937;
RX   PubMed=23699601;
RX   PubMed=25960936;
WW   http://www.innovationbridge.com/uhn/diffuse-large-b-cell-lymphoma-cell-lines?categories=32&communities=5&forums=&organizations=&tags=
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Doubling time: ~50-60 hours (DSMZ).
CC   HLA typing: A*02:01; C*05:01,05:01 (PubMed=25960936).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Genome sequenced.
CC   Omics: H3K9ac ChIP-seq epigenome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Bone marrow.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 9
ST   D5S818: 11,12
ST   D7S820: 11
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-10-20; Version: 24
//
RX   PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307;
RA   Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R.,
RA   Lockwood G., Minden M.D., Messner H.A.;
RT   "The presence of clonogenic cells in high-grade malignant lymphoma: a
RT   prognostic factor.";
RL   Blood 69:1307-1314(1987).
//
RX   PubMed=8574164; DOI=10.3109/10428199509059672;
RA   Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.;
RT   "p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's
RT   lymphoma cell lines.";
RL   Leuk. Lymphoma 19:165-171(1995).
//
RX   PubMed=10676951; DOI=10.1038/35000501;
RA   Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S.,
RA   Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I.,
RA   Yang L., Marti G.E., Moore T., Hudson J. Jr., Lu L., Lewis D.B.,
RA   Tibshirani R., Sherlock G., Chan W.C., Greiner T.C.,
RA   Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W.,
RA   Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M.;
RT   "Distinct types of diffuse large B-cell lymphoma identified by gene
RT   expression profiling.";
RL   Nature 403:503-511(2000).
//
RX   PubMed=11807979; DOI=10.1002/gcc.10025;
RA   Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.;
RT   "Molecular cytogenetic characterization of non-Hodgkin lymphoma cell
RT   lines.";
RL   Genes Chromosomes Cancer 33:225-234(2002).
//
RX   PubMed=12169673; DOI=10.1016/S1525-1578(10)60693-9;
RA   Robetorye R.S., Bohling S.D., Morgan J.W., Fillmore G.C., Lim M.S.,
RA   Elenitoba-Johnson K.S.J.;
RT   "Microarray analysis of B-cell lymphoma cell lines with the
RT   t(14;18).";
RL   J. Mol. Diagn. 4:123-136(2002).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C., Naresh K., Evens A., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
//
RX   PubMed=23699601; DOI=10.1182/blood-2013-02-483727;
RA   Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R.,
RA   Huff R.D., Scott D.W., Ding J., Roth A., Chiu R., Corbett R.D.,
RA   Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G.,
RA   Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B.,
RA   Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S.,
RA   Steidl C., Holt R., Birol I., Moore R., Connors J.M., Gascoyne R.D.,
RA   Marra M.A.;
RT   "Mutational and structural analysis of diffuse large B-cell lymphoma
RT   using whole-genome sequencing.";
RL   Blood 122:1256-1265(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//